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This dissertation describes the design and synthesis of class II Major Histocompatibility 
Complex (MHC) blockers through secondary structure modification of antigenic peptide, 
and the discovery of a novel cell penetrating peptide - 33mer, from wheat proteins called 
‘gliadins’. 
 
 Previously, peptidomimetic class II MHC blockers were designed by modifying the 
sequence of antigenic peptides which associate with MHC proteins. A drawback of this 
approach lies in the fact that such modifications are highly specific to a particular class II 
MHC protein and cannot be applied for designing blockers against other MHC 
molecules. This thesis demonstrates a novel approach of designing MHC binders through 
structural modification of antigenic peptide. As it was previously reported that antigenic 
peptides bound to most of the class II MHC molecules adopt a common Polyproline II 
(PPII) helical secondary structure, the strategy of developing MHC binders through 
structural modification of antigenic peptides may be applied to develop blockers against  
multiple class II MHC molecules. By synthesizing a library of antigenic peptide 
analogues with varying degrees of PPII conformations, we demonstrate that some of the 
structurally modified analogues display higher binding affinity to HLA-DQ2 - a class II 
MHC protein, and also display superior suppression of T-cell proliferation of two specific 




Cell penetrating peptides (CPPs) are short peptides ranging from 7 to 40 amino acids in 
length and have the ability to cross plasma membrane and gain entry into cells. CPPs are 
capable of delivering biologically active cargo to the cell interior and the cargo ferrying 
capabilities of these peptides have already been harnessed for in vitro applications. One of the 
major drawbacks of the existing CPPs is their susceptibility to digestive proteases and 
this property severely restricts the use of existing CPPs for drug delivery applications in 
vivo. This dissertation reports the discovery of a novel, protease resistant CPP - 33mer. 
Compared to the existing CPPs, this 33mer peptide is resistant to gastric and pancreatic 
proteases and therefore has potential therapeutic and diagnostic applications. The cell 
penetration ability of 33mer peptide is demonstrated with flow cytometry and confocal 
microscopy techniques and the protease resistant nature of 33mer is highlighted through 
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Introduction to Major Histocompatibility Complex (MHC) Molecules  
 
The immune system is a complex network of cells, tissues, and organs that operate in an 
interdependent manner to defend the host from attack by foreign organisms. This system 
in vertebrates is broadly classified into innate and adaptive immune system. 
 
Innate immune system comprises of elements which offer immediate host response. An 
important property of this system is its non-specificity towards the invading pathogens.  
This system consists of several key molecules, which include proteins from the 
complement system, Interleukins and an array of cells like Neutrophils, Macrophages, 
Dendritic cells, Natural Killer (NK) cells etc.  
 
Adaptive immune system comprises of components which elicit a highly specific 
response against pathogens. In comparison to innate immunity, adaptive immune system 
takes a longer time to become fully activated. It mainly consists of a specific type of 
White Blood Cells (WBC), called lymphocytes. Depending on the location of maturation, 
they are classified into B-lymphocytes (maturation site: bone marrow) and T-
lymphocytes (maturation site: thymus). The B-lymphocytes mediate immune attack 
through soluble glycoproteins called antibodies which have high specificity to their target 
antigen. A class of T-lymphocytes called T-cytotoxic cells elicits cell mediated immune 
response, wherein they identify and neutralize the pathogens. Other types of T-
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lymphocytes, namely T-helper cells, memory and regulatory T-cells also play a vital role 
in launching an effective and targeted immune response. One of the striking properties of 
adaptive immunity is memory. This property enables the adaptive immune system to 
generate immune response in a much shorter time, during subsequent attacks by the same 
pathogen. 
 
1.3 Antigen Presenting Cells and Major Histocompatibility Complex Proteins 
Innate immunity is body's first line of defense. After recognition of the pathogen by the 
innate immune system, a crucial process involved in mounting an effective immune 
response, is the activation of adaptive immunity. Specific cells namely, Antigen 
Presenting Cells (APC's) play an important role in facilitating this process. 
 
APC's are specialized cells which degrade foreign protein antigens into peptides and 
display them on their surface through specific membrane bound glycoproteins called 
Major Histocompatibility Complex (MHC) molecules. In humans, MHC proteins are 
termed as Human Leukocyte Antigens (HLA).  
 
1.3.1 MHC Molecules - An overview 
MHC molecules are cell surface proteins encoded by closely linked genetic loci present 
on chromosome 6 in humans. They can be broadly classified in to two major classes 
namely class I and class II MHC molecules. Both class I and II MHC molecules have 
certain common functions which include response to tissue grafting and control of 
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immune responses. These functions result from the ability of MHC molecules to bind 
antigenic peptides and present them to T-cells. Figure 1 shows crystal structure of class II 
MHC molecule (HLA-DR4) bound to antigenic peptide (influenza hemagglutinin, 
HA306–318), interacting with human alpha/beta T cell receptor (TCR) HA1.7. In the 
MHC-peptide-TCR interaction, the complementarity determining regions (CDR) from 
TCR interact with both antigenic peptide and MHC molecules resulting in the activation 
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Figure 1. Crystal structure of MHC- peptide - T-cell receptor (TCR) tri-complex 
The complex between TCRs and antigenic peptide-class II MHC molecule involves interactions 
between residues from Vα and Vβ domains of TCR, and residues on both, MHC molecule and the 
bound antigenic peptide. The class II MHC molecule HLA-DR4 (DR4 is an allelic form of HLA-
DR protein) is shown in green; the antigenic influenza hemagglutinin peptide, HA306–318 bound 
to the peptide-binding groove of HLA-DR4 is shown in violet; the TCR is shown in light blue. 
Protein Data Bank code of this protein is 1J8H. Molecular visualizations for this figure were 








1.3.1.1 Class I MHC Molecules 
 
Class I MHC molecules are composed of 2 chains, a heavy chain (α- chain) and a light 
chain (β-chain). The heavy chain comprises of 3 domains - α1, α2 and α3, followed by a 
transmembrane domain, and a cytoplasmic domain. α1 and α2 domains are highly 
polymorphic and form a cavity which accommodates peptides that are 8-11 amino acids 
long. The heavy chain is encoded by 3 genes namely HLA-A, HLA-B and HLA-C with 
more than 350 alleles for HLA-A, 620 alleles for HLA-B and 40 alleles for HLA-C. The 
light chain, also called beta-2-microglobulin (β2m) is associated with the heavy chain 
through non covalent interactions and does not contribute to the formation of peptide 
binding pocket. Both, heavy and light chains of Class I MHC molecules are assembled in 
the endoplasmic reticulum (ER) [2].  
 
Peptides derived from the cytosol, formed mainly by the action of proteasomes, are 
transported into the lumen of ER where they bind to the peptide binding groove of class I 
MHC proteins. The resulting MHC-peptide complex is subsequently transported through 
golgi complex to the plasma membrane. On the plasma membrane, this MHC-peptide 
complex interacts with the T cell receptor (TCR) found on the surface of CD8+ T cells. 
This process plays an important role in development of CD8+ T cells in the thymus, their 
activation and proliferation in the periphery [3]. MHC class I molecules are expressed by 
almost all nucleated cells in the body. 
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1.3.1.2 Class II MHC Molecules 
 
Class II MHC molecules are heterodimeric glycoproteins comprised of two subunits - α 
subunit and the β subunit.  In contrast to class I MHC molecules, both α and β subunits 
together form the peptide binding grove which accommodates antigenic peptides ranging 
from 9 to 40 amino acids in length.  Both, α and β subunits are synthesized and directed 
to ER where they assemble with the invariant chain (Ii). The Ii chain occupies the class II 
MHC binding pocket. The MHC-Ii molecules are transferred to the golgi network where 
they undergo post translational modification and enter specialized endocytic 
compartments. The Ii chain prevents the degradation of MHC molecules and also blocks 
the binding of self peptides to MHC molecules before they are exposed to antigenic 
peptides. Three highly polymorphic genes namely HLA-DP, HLA-DR and HLA-DQ 
encode α and β subunits of MHC proteins. The structural differences between class I and 















                  
  
Figure 2.  Schematic representation of class I and class II MHC molecules  
A class I MHC molecule consists of two chains namely, α chain composed of three domains 
(designated as α1, α2, and α3), and the second chain named β2-microglobulin (β2m). A class II 
MHC molecule consists of α chain and β chain. Both the chains are folded into domains namely 
α1 and β1 domains which are distal from the cell membrane, and membrane proximal α2 and β2 
domains. In class I MHC molecules, the peptide binding region is formed by α chain alone, 
whereas in class II MHC molecules, domains from both α and β chains together form the peptide 






Class II MHC proteins sample antigenic peptides obtained through antigen processing 
pathway. The antigenic proteins acquired through phagocytosis, pinocytosis and 
endocytosis reach lysosomes where they are digested into smaller peptides. These 
lysosomes fuse with endocytic vesicles carrying the class II MHC-Ii molecules.  The Ii 
chain of class II MHC molecules is digested in these lyso-endosomal compartments 
Class I MHC Class II MHC 




leaving a small peptide in the MHC binding pocket, which is referred to as CLIP (Class II 
associated invariant chain peptide). CLIP is released and exchanged for an antigenic 
peptide fragment through a mechanism which involves a catalytic protein, HLA-DM. 
HLA-DM is a non-polymorphic heterodimer, and its structure is similar to the general 
fold of a conventional class II MHC molecule. This molecule catalyses the exchange of 
CLIP with antigenic peptides. MHC-antigenic peptide complex formed in this manner is 
transported to the cell surface where it is presented to CD4+ T-cells [4]. The interaction 
of class II MHC-antigenic peptide complex and the TCR, along with other co-stimulatory 
signals induces a helper T-cell mediated immune response. Major steps involved in the 



















Figure 3. Schematic representation of antigen loading on class II MHC molecules 
Class II MHC molecules bound to invariant chain are synthesized in endoplasmic reticulum and 
transported to specialized endosomal compartment where the invariant chain is cleaved, leaving a 
small peptide CLIP in the peptide binding region. Exogenous antigens that are taken up by 
endocytosis are cleaved into small peptide fragments within the endosomes and reach the 
compartment for peptide loading through fusion of endosomal vesicles. Here, the CLIP fragment 
is eventually replaced by the cleaved antigenic peptides and peptide-MHC complexes are 
delivered to the cell surface. CPL: compartment for peptide loading, Calnexin: chaperone present 





Source: Sioud Mouldy (2006), Target Discovery and Validation Reviews and Protocols, 1st ed., Humana 
Press Inc. 277-318 
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1.3.2 Association of Antigenic Peptides to Class II MHC Molecules 
Over 50 crystal structures of different human and murine class II MHC molecules in 
complex with various antigenic peptides have been determined over the past decade. 
Analysis of these crystal structures suggests that all MHC molecules show a similar 
overall structure. Class II MHC proteins are composed of two polypeptide chains namely 
α- and β-chain. These chains associate in a non covalent manner to form the peptide 
binding groove. The floor of this groove comprises of 8-stranded antiparallel beta sheet 
contributed equally by α and β chains. Two antiparallel alpha helices (up to 45 amino 
acids in length) constitute the walls of binding groove. Antigenic peptides ranging from 8 
to 35 amino acids in length bind to this groove and are displayed to T helper cells, a 
process which can potentially result in the activation of adaptive immune system. 
 
Analysis of the existing MHC structures also revealed that the antigenic peptides adopt 
an elongated polyproline II (PPII) like helical structure in the binding pocket. Multiple 
hydrogen bonds formed between conserved residues in the class II MHC protein and the 
antigenic peptide main chain carbonyl and amide groups stabilize the peptide-MHC 
interaction. Antigenic peptides associated with class II MHC proteins are usually 9 to 20 
amino acids in length. A stretch of 9 amino acids from the antigenic peptide occupies the 
binding groove of class II MHC, in a sequence specific manner. The side chains of amino 
acids present specifically in P1, P4, P6 and P9 positions of the antigenic peptide occupy 
distinct pockets present in the class II MHC molecule. This pattern can be observed in all 
class II MHC molecules except in specific alleles of HLA-DR, namely HLA-DR2a and 
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HLA-DR2b. These pockets correspond to positions where strong side chain preferences 
are observed in the studies of MHC- peptide interaction [5]. A crystal structure of class II 
MHC molecule (HLA-DQ2) in complex with antigenic peptide, α-1-gliadin is 
represented in figure 4 
      
Figure 4. Crystal structure of α-I-gliadin peptide bound to HLA-DQ2  
HLA-DQ2, an allelic form of HLA-DQ type, class II MHC molecule is composed of 2 chains, α-
chain shown in green and β chain represented in light blue. Both the chains together constitute the 
binding groove of the HLA-DQ2 which consists of a beta sheet floor and two alpha helical walls. 
The peptide α-1-gliadin, (C, yellow; N, blue; O, red), is bound in an extended, type II polyproline 
helix conformation in the binding groove of HLA-DQ2. Protein Data Bank code of this protein is 





Since each class II MHC molecule can present different peptides to TCR, low degree of 
selectivity drives the interaction between peptides and MHC proteins. It was previously 
demonstrated that most peptides capable of binding to a specific MHC molecule show 
high diversity in their sequence[6]. In fact, interactions between peptides and MHC 
proteins usually tolerate up to 80-90% of single amino acid substitutions in the sequence 
of peptide. However, recognition of the peptide-MHC complex by the T cell receptor is 
highly specific and allows for 10-20% of single amino acid substitutions in a given 
peptide[7]. One consequence of this broad-range specificity of peptide-MHC interactions 
is that peptides of different sequences may compete for antigen presentation by a given 
MHC molecule.  
Previously, it was demonstrated that antigenic peptides  binding  to  the  same MHC  
molecule can compete with each other for presentation to T cells[8]. Several independent 
experiments have demonstrated a correlation between the capacity of a peptide to bind to 
MHC molecules, and its ability to compete with other peptides binding to the same MHC 
protein [9-11] 
 
1.4 Introduction to MHC Blockers 
 
MHC blockers are molecules which bind to specific MHC protein, and inhibit the 
activation of T cells by antigenic peptides binding to the same molecule. A subset of 
MHC blockers, called Altered Peptide Ligands (APL) are molecules in which amino acid 
replacements in antigenic peptides lead to modified interaction with the TCR, and alters 
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activation of the T cells. Previously, APLs were designed through a process of systematic 
Alanine substitution of amino acid residues in disease associated antigenic peptides (T-
cell epitopes) and monitoring its effects on T-cell proliferation in vitro and disease 
progression in vivo[12]. Recently, APL's were developed by glycosylation of T-cell 
epitopes[13].  
HLA-DR molecules are class II MHC proteins associated with several autoimmune 
diseases like Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Systemic Lupus 
Erythematosus (SLE) etc. Previously, several strategies were adopted to design blockers 
against HLA-DR molecules. Bolin et al. designed antigenic analogue blockers using a 
combination of modified amino acids and dipeptide analogues[14]. Based on the crystal 
structure of the HLA-DR1: HA peptide complex, and binding motif information 
generated by panning M13 phage expressed random peptide libraries, Bolin and 
colleagues selected Ac-YRAMASL-NH2 as the initial consensus sequence. Analogues 
for this sequence were generated by incorporating various unnatural amino acids like 
cyclohexylalanine, norbornylalanine, allo-isoleucine, dimethylornithine etc., and 
dipeptide mimetics such as 9-aminooctahydro-6,10-dioxo-6H- pyridazino-[1,2-
a][1,2]diazepine-1-carboxylic acid (Odapdc), 5-amino-1,2,4,5,6,7-
hexahydroazepino[3,2,1-hi] indol-4-one-2-carboxylic acid (Haic). These analogues were 
able to compete effectively against disease causing antigenic peptides in cellular assays, 
resulting in inhibition of T-cell proliferation. 
In a separate set of experiments, Cotton et al. designed analogues of antigenic peptide by 
replacing each amide bond of the peptide, either by a reduced or N-methylated peptide 
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bond[15]. Some of these analogues displayed low binding capacity to MHC molecules, 
however, they successfully inhibited T-cell activation. Hart et al. demonstrated that 
antigenic peptides substituted with aza-amino acids showed detectable MHC binding and 
weak T-cell activation[16].  
Woulfe et al. synthesized a library of peptidomimetics of influenza virus haemagglutinin 
peptide, HA307-319 by introducing various chemical groups like 3-phenylbutyric acid, 
pipecolic acid, propylamine and cyclohexylalanine. These peptidomimetic compounds 
were highly specific for HLA-DR4 and they also inhibited functional T cell responses to 
peptide antigens[17]. Recently, Xia et al. designed dimeric and cyclic antigenic peptide 
analogues for blocking antigen presentation by HLA-DQ2. The cyclic analogues were 
designed by synthesizing peptides containing the DQ2 - α-I-gliadin epitope  
(LQPFPQPELPY) with flanking cysteine residues introduced and subsequently 
crosslinked through a disulfide bond. Dimeric analogues were designed by dimerizing the 
antigenic peptide (LQLQPFPQPEKPYPQPELPY) through lysine side chains. The effect 
of cyclization as well as the linker length between dimeric analogues, on DQ2 binding 
and T cell recognition was analyzed. A dimeric peptide analogue with an intermediate 










Design of Novel Class II MHC Blockers through Secondary Structure 
Modification of Antigenic Peptide 
2.1 Introduction 
2.1.1 Design of MHC Blockers through Secondary Structure Modification of 
Antigenic Peptide 
 
As described earlier, MHC blockers are molecules which bind to specific MHC protein, 
and inhibit the activation of T cells by antigenic peptides binding to the same molecule. 
Previously, MHC blockers were mainly designed by altering the interactions between 
side chains of antigenic peptides and MHC molecules, as well as interactions of this 
peptide-MHC complex with T-cell receptors (TCR). These blockers were designed 
through amino acid substitution or by introducing unnatural amino acids, dipeptide 
mimetics etc. in the antigenic peptide sequence. Since this approach is targeted at 
modifying existing interactions between antigenic peptides and MHC protein, these 
modifications are highly specific to a given MHC-peptide-TCR system and may not be 
applied to design blockers against other class II MHC molecules. To overcome this 
limitation, there is a need to design MHC blockers by altering those characteristics of 




Earlier, spectroscopic techniques were used to investigate the association between 
structure of MHC binding peptides and their antigenicity [19-21]. Simulation studies 
suggested that ordered regions such as amphipathic or α- helices [22, 23] and β-sheet 
structures [24]  are frequently found within T cell epitopes. Based on structural data 
obtained from X-ray crystallography, Jardetzky et al. [25] proposed that antigenic 
peptides adopt a polyproline II (PPII) like conformation in the binding pocket of class II 
HLA molecule.  
 
Based on the crystal structure of class II MHC protein HLA-DQ2 in complex with 
antigenic peptide α-I-gliadin, Kim C.Y. et al. proposed that the Pro rich nature of α-I-
gliadin imparts a PPII helical conformation to the peptide and this in turn promotes the 
binding of such peptides to DQ2[26]. This hypothesis has important implications in the 
field of immunology and drug design. If the secondary structure of a peptide contributes 
to its binding affinity to class II MHC molecules, this provides an opportunity to screen 
for class II MHC binding epitopes based on their secondary structure. Also, high affinity 
MHC blockers may be produced by engineering the PPII conformation into the structure 
of blocker molecules.  
 
In the current work, the relationship between the solution conformation of peptides and 
their MHC association rate was explored. By generating a library of MHC binding 
analogues of antigenic peptide with varying degree of inherent PPII conformations, the 
effect of peptide secondary structure on the binding ability to class II MHC molecule was 
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probed. Some of these structurally modified peptides display higher binding affinity to 
DQ2 compared to antigenic peptide, and also suppress the proliferative response of two 
antigen specific T-cell lines. 
 
2.1.2 HLA-DQ2 and α-I- gliadin as an experimental system 
 
HLA-DQ2 is a class II MHC molecule strongly associated with an autoimmune disorder 
Celiac Disease (CD). CD is triggered by consumption of dietary wheat. Upon 
consumption, gluten protein found in wheat is digested into smaller peptides called 
gliadins. In genetically susceptible individuals (those expressing HLA-DQ2 or -DQ8), 
these gliadin peptides are restricted by class II MHC molecules, HLA-DQ2/DQ8 and this 
gliadin peptide-DQ2/DQ8 complex is recognized by gluten reactive CD4+ T-cells, 
resulting in the activation of the adaptive immune system [27]. A high resolution, X-ray 
crystal structure of HLA-DQ2 in complex with one of the antigenic peptides - α-I- gliadin 
(QLQPFPQPELPY) was reported in 2004 [26]. Due to the availability of detailed 
structural information and access to soluble DQ2 molecules, α-I- gliadin bound to HLA-
DQ2 was selected as model system.  
 
2.1.3 Design of structurally diverse α-I- gliadin analogue library 
 
Previously Sette et al. [28] demonstrated that antigenic peptides do not adopt canonical 
structures like α-helix or β-sheet in solution. Since it was reported that MHC ligands 
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adopt PPII helical structure in the bound conformation[25], we designed analogues of α-
I-gliadin, which varied in their PPII propensity in solution. A library consisting of 11 
peptide analogues was synthesized with a range of PPII propensities, using the antigenic 
α-I- gliadin peptide as template. From the crystal structure, the first three, N-terminal 
amino acids of α-I-gliadin (QLQ) lie outside the peptide binding groove of DQ2. The 
sequence PFPQPELPY occupies the peptide binding groove of DQ2 and the residues are 
numbered from P1 to P9, where P1 is Pro and P9 is Tyr. Data from this crystal structure 
suggests that amino acids in positions P1, P4, P6 and P7 of α-1-gliadin interact with the 
DQ2 and are crucial for anchoring the antigenic peptide to the MHC molecule. Amino 
acid Glu (P6) takes part in a complex set of non covalent interactions with DQ2 and plays 
a major role in stabilizing the complex. Amino acids Pro (P1), Gln (P4) and Leu (P7) are 
involved in van der Waals interactions with the binding pocket of the MHC molecule. On 
the other hand, side chains of amino acids present in positions P2, P3, P5 and P8 are 
mostly solvated and make limited interactions with DQ2. In the case of Phe (P2), both the 
amide and carboxyl groups participate in hydrogen bond interaction with HLA-DQ2[26]. 
The crystal structure of α-1-g peptide bound to HLA-DQ2 highlighting the orientation of 




Based on this information, we designed the analogue library by modifying α-1-gliadin at 
position P3, P5 and P8. Previous epitope scanning experiments also indicated that the P5 
residue of α-1-gliadin does not participate in any interactions with DQ2 [29]. By 
modifying the solvent exposed residues alone, and having the anchoring residues 
unmodified, we hypothesize that the enthalpic signature of interactions of all peptides in 
the library with HLA-DQ2 would remain similar. 
 
 
Figure 5. Crystal structure of α-1-g peptide bound to HLA-DQ2  
The peptide α-1-gliadin, (C, yellow; N, blue; O, red), adopts an extended, type II polyproline 
helix conformation in the binding groove of HLA-DQ2. The side chains of amino acids in 
positions P1, P4, P6 and P7 of α-1-gliadin interact with the DQ2 and are crucial for anchoring the 
antigenic peptide to the MHC molecule, whereas the side chains of amino acids in positions P2, 
P3, P5 and P8 of α-1-gliadin do not interact with HLA-DQ2 and are exposed to solution. The 
analogue library was designed by substituting these solvent exposed residues in position P3, P5 
and P8. Protein Data Bank code of this protein is 1S9V. Molecular visualizations for this figure 





2.1.4 Choice of amino acids for positions P3, P5 and P8 of α-I-gliadin 
Previously, Creamer et al. [30, 31] published reports on the propensity of individual 
amino acids to promote PPII conformation in the parent peptide. Proline (Pro), Alanine 
(Ala) and Glutamine (Gln) were reported to have higher propensity to promote PPII 
structure compared to branched amino acids like Leucine (Leu) Isoleucine (Ile) and 
Valine (Val). Cherng et al. [32] reported the propensity of Hydroxyproline (Hyp) to 
promote PPII conformation to a greater extent compared to Proline. They demonstrated 
that (Hyp)10 peptide adopts greater PPII conformation than (Pro)10 peptide under aqueous 
conditions. Suode et al. [33], solved the crystal structure of poly N-methylated alanine 
peptide (N-MeAla) and reported that it adopts an elongated beta strand conformation. 
Based on these reports, amino acid substitutions were made at P3, P5 and P8 positions of 
α-1-gliadin with Hyp, which that promotes PPII propensity. These analogues were 
expected to have higher PPII propensity in solution compared to native α-1-gliadin 
peptide. To generate analogues with lower PPII propensity, N-MeAla which promotes 
elongated β-strand conformation was introduced in position P3, P5 and P8. In this 
manner, 11 peptide analogues of α-I-gliadin were designed, which are expected to have 
similar enthalpic interactions with DQ2 (due to similar anchoring residues in positions 
P1, P4, P6, P7 and P9) but differ in their propensity to adopt PPII conformation in 







Table 1. Amino acid sequences of structurally diverse α-I- gliadin analogues  
 
 
-3 -2 -1 P1 P2 P3 P4 P5 P6 P7 P8 P9 
α-I-g Q L Q P F P Q P E L P Y 
A1 Q L Q P F Hyp Q Hyp E L Hyp Y 
A2 Q L Q P F Hyp Q P E L Hyp Y 
A3 Q L Q P F Hyp Q Hyp E L P Y 
A4 Q L Q P F P Q Hyp E L Hyp Y 
A5 Q L Q P F P Q P E L Hyp Y 
A6 Q L Q P F P Q Hyp E L P Y 
A7 Q L Q P F Hyp Q P E L P Y 
A8 Q L Q P F N-Me-ala Q P E L P Y 
A9 Q L Q P F P Q N-Me-ala E L P Y 
A10 Q L Q P F N-Me-ala Q P E L N-Me-ala Y 
A11 Q L Q P F N-Me-ala Q N-Me-ala E L P Y 
A12 Q L Q P F P Q N-Me-ala E L N-Me-ala Y 
 
Note: All the peptides have a 5, 6 carboxyfluorescein molecule attached to their N-
terminus 
α-I-g - α-I-gliadin 
 Hyp - Hydroxyproline 




2.2 Experimental Section 
 
2.2.1 Peptide synthesis, Labeling and Purification 
 
Peptides used in this study were synthesized manually using standard Fmoc/HBTU 
chemistry based solid phase peptide synthesis (SPPS) with wang resin as a solid support. 
Peptides were labeled at their N-termini with 5- (and 6- ) carboxyfluorescein (2.5 fold 
molar excess) using N,N'-diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole 
(HOBt) in 1:1 dimethyl formamide (DMF) and dichloromethane (DCM) as solvent.  
After completion of synthesis, peptides were cleaved from resin in trifluoroacetic 
acid/triisopropylsilane/water (TFA/TIS/H2O 95:2.5:2.5, v/v/v) for 4 hours and 
precipitated in ice cold methyl tert-butyl ether (MTBE). Crude peptides were lyophilized 
and were purified by reverse-phase HPLC on a semi-preparative C18 column using a 
water-acetonitrile gradient in 0.05% (v/v) TFA, to purity greater than 95%. The purity 
and identity of the peptides were confirmed by liquid chromatography coupled 
electrospray mass spectrometry (LC-MS). The pure fractions were lyophilized and stored 
at −20°C. 
 
2.2.2 Circular Dichroism 
 
Circular dichroism (CD) spectra were measured on a Jasco J810 spectropolarimeter as 
per standard operating procedures. The peptide samples were prepared to a final 
concentration of 35 uM, in 1:1 mixture of PBS and McIlavaine’s buffer with final pH adjusted 
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to 5.4 and temperature maintained at 370C. Spectra were recorded with a quartz cell of 0.1 
cm path length. Scanning was performed at a resolution of 0.1nm, across wavelengths 
ranging from 190 nm to 240 nm. The temperature was maintained at 370 C using peltier 
temperature control system. Data collected is represented in millidegrees (mdeg). The CD 
spectra represent an average of ten accumulations, and were corrected by subtracting the 
buffer base line. No additional smoothing was performed.  
 
2.2.3 Peptide Exchange Assay 
 
Peptide exchange experiments were carried out as described previously [29, 34]. The 
DQ2 heterodimer with covalently linked peptide was pretreated with thrombin [40:1 
(w/w)] for 90 minutes at 00C, followed by incubation in protease inhibitor cocktail for 
additional 30 minutes, on ice. The resulting protein was incubated with fluorescein-
conjugated native peptide, and its analogues at 25:1 ratio (i.e. 5.0 µM DQ2 with 0.2 µM 
fluorescent analogue). Incubations were carried out at 37°C in 1:1 mixture of PBS buffer 
and McIlvaine’s citrate-phosphate buffer such that the final pH was 5.5. Analogues were 
incubated with DQ2 for 2 hours during which, binding was monitored every 30 min. 
Association of analogues to DQ2 was measured by High Performance Size Exclusion 
Chromatography (HPSEC). Two micro liters of reaction mixture was injected onto a 
Shodex RW 803 size exclusion column using an auto injector and eluted with PBS buffer 
at 0.7 ml/min. The fluorescence signal was recorded using an in-line Shimadzu RF 10-
AxL fluorescent detector with excitation wavelength set at 495 nm and emission 
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wavelength set at 517 nm. The area under the peak from DQ2-analogue complex and 
analogue alone were used to quantify the amount of complex formed. 
 
2.2.4 T-cell Proliferation Assay 
 
T cell clones reactive to gluten were established from small intestinal biopsies of patients 
suffering from CD. These include T cell clone, TCC 430.1.41 and TCC 437.1.3.17 (both 
specific for γ-II gliadin epitope (GIIQPEQPAQL), restricted by DQ2). In addition a DR3-
restricted T cell clone, TCC RN.33 (specific for the 3–13 epitope of Mycobacterium 
tuberculosis heat shock protein 65, KTIAYDEEARR), was also established. HLA-
DR3/DQ2 homozygous Epstein-Barr virus transformed B-lymphoblastoid cell lines 
(CD114) were used as Antigen Presenting Cells (APC’s) .The cells were fixed with 1% 
paraformaldehyde for 10 min or with 0.05% glutaraldehyde for 90 s using 0.2M glycine 
to quench the reaction. The assay was performed as previously described [29]. Peptides 
were incubated with APC’s overnight, with specific concentrations of antigenic peptide 
(γ-II gliadin) alone, or antigenic peptide in the presence of different concentrations of 
analogues, in media containing human serum supplemented with antibiotics. A 96 well 
plate was used for this purpose. An equal density of T cells was added to each well, and 
cells were incubated at 37°C and 5% CO2 for 48 h, at which time 0.5 µCi/well of 
[methyl-3H] thymidine or 1 µCi/well of [methyl-3H] thymidine was added. Cells were 
incubated for an additional 12–14 h and then frozen. After thawing, incorporated 
thymidine was collected on a filter mat using a Tomtec cell harvester, and counted using 




2.3.1 HPLC and MS Profiles of Peptides in Analogue Library 
 
All the peptides in the library were purified using Shimadzu LC-6AD preparative 
H.P.L.C. using a Phenomenex C18 semi preparative column. Two buffers, Buffer A (98% 
H20, 2 % Acetonitrile and 0.05% Trifluoroacetic acid) and Buffer B (80% Acetonitrile, 
20% H2O and 0.04% Trifluoroacetic acid) were used for purification. The purity was 
confirmed to be greater than 95% by using a C18 analytical column. The analytical 
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Figure 6. LC-ESI-MS profile of peptide α-I-gliadin. A) Liquid chromatogram of the 
peptide α-I-gliadin. Chromatographic conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile 
phase: Buffer A: 98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 
0.04% TFA; Gradient: 0 - 80% B in 80 min.B) ESI-MS of peptide α-I-gliadin dissolved in 0.1% 
TFA aqueous solution. Expected Molecular Weight: 1815 Da [MH] +, 908.5 Da [MH2]2+ 
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Figure 7. LC-ESI-MS profile of Analogue A1. A) Liquid chromatogram of analogue A1. 
Chromatographic conditions: Luna C-18 (50 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 
98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA; Gradient: 
0 - 80% B in 80 min.B) ESI-MS of peptide α-I-gliadin dissolved in 0.1% TFA aqueous solution. 
Expected Molecular Weight: 1863 Da [MH] +, 932.5 Da [MH2]2+ 
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Figure 8. LC-ESI-MS profile of Analogue A2. A) Liquid chromatogram of the analogue 
A2. Chromatographic conditions: Luna C-18 (50 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 
98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA; Gradient: 
0 - 80% B in 80 min.B) ESI-MS of peptide α-I-gliadin dissolved in 0.1% TFA aqueous solution. 
Expected Molecular Weight: 1847 Da [MH] +, 924.5 Da [MH2]2+ 
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Figure 9. LC-ESI-MS profile of Analogue A3. A) Liquid chromatogram of the analogue 
A3. Chromatographic conditions: Luna C-18 (50 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 
98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA; Gradient: 
0 - 80% B in 80 min.B) ESI-MS of peptide α-I-gliadin dissolved in 0.1% TFA aqueous solution. 
Expected Molecular Weight: 1847 Da [MH] +, 924.5 Da [MH2]2+ 
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Figure 10. LC-ESI-MS profile of Analogue A4. A) Liquid chromatogram of the analogue 
A4. Chromatographic conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 
98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, Gradient: 
0 - 80% B in 80 min; B) ESI-MS of peptide A4 dissolved in 0.1% TFA aqueous solution. 
Expected Molecular Weight: 1847 Da [MH] +, 924.5 Da [MH2]2+ 
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Figure 11. LC-ESI-MS profile of Analogue A5. A) Liquid chromatogram of the analogue 
A5. Chromatographic conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 
98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, Gradient: 
0 - 80% B in 80 min; B) ESI-MS of peptide A5 dissolved in 0.1% TFA aqueous solution. 
Expected Molecular Weight: 1831 Da [MH] +, 916.5 Da [MH2]2+ 









































































































Figure 12. LC-ESI-MS profile of Analogue A6. A) Liquid chromatogram of the analogue 
A6. Chromatographic conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 
98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, Gradient: 
0 - 80% B in 80 min; B) ESI-MS of peptide A6 dissolved in 0.1% TFA aqueous solution. 
Expected Molecular Weight: 1831 Da [MH] +, 916.5 Da [MH2]2+ 












































































































Figure 13. LC-ESI-MS profile of Analogue A7. A) Liquid chromatogram of the analogue 
A7. Chromatographic conditions: Luna C-18 (50 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 
98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, Gradient: 
0 - 80% B in 80 min; B) ESI-MS of peptide A8 dissolved in 0.1% TFA aqueous solution. 
Expected Molecular Weight: 1831 Da [MH] +, 916.5 Da [MH2]2+ 
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Figure 14. LC-ESI-MS profile of Analogue A8. A) Liquid chromatogram of the analogue 
A8. Chromatographic conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 
98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, Gradient: 
0 - 80% B in 80 min; B) ESI-MS of peptide A8 dissolved in 0.1% TFA aqueous solution. 
Expected Molecular Weight: 1803 Da [MH] +, 902 Da [MH2]2+ 






































































































Figure 15. LC-ESI-MS profile of Analogue A9. A) Liquid chromatogram of the analogue 
A9. Chromatographic conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 
98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, Gradient: 
0 - 80% B in 80 min; B) ESI-MS of peptide A9 dissolved in 0.1% TFA aqueous solution. 
Expected Molecular Weight: 1803 Da [MH] +, 902 Da [MH2]2+ 
 







































































































Figure 16. LC-ESI-MS profile of Analogue A10. A) Liquid chromatogram of the analogue 
A10. Chromatographic conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer 
A: 98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, 
Gradient: 0 - 80% B in 80 min; B) ESI-MS of peptide A10 dissolved in 0.1% TFA aqueous 
solution. Expected Molecular Weight: 1792 Da [MH] +, 896 Da [MH2]2+ 











































































































Figure 17. LC-ESI-MS profile of Analogue A11. A) Liquid chromatogram of the analogue 
A11. Chromatographic conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer 
A: 98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, 
Gradient: 0 - 80% B in 80 min; B) ESI-MS of peptide A11dissolved in 0.1% TFA aqueous 
solution. Expected Molecular Weight: 1792 Da [MH] +, 896 Da [MH2]2+ 











































































































Figure 18. LC-ESI-MS profile of Analogue A12. A) Liquid chromatogram of the analogue 
A12. Chromatographic conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer 
A: 98%water + 2% ACN + 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, 
Gradient: 0 - 80% B in 80 min; B) ESI-MS of peptide A12 dissolved in 0.1% TFA aqueous 
solution. Expected Molecular Weight: 1792 Da [MH] +, 896 Da [MH2]2+ 
 








































































































2.3.2 Circular Dichroism (CD) Spectroscopic Analysis of Analogue Library 
 
The analogue library was subjected to C.D. spectroscopic analysis as described in 
experimental section. A stable PPII helix of a poly L-proline peptide in aqueous 
conditions has a characteristic negative peak at 210 nm (π- π * transition) and a weak 
positive peak around 229 nm (n- π * transition) [35] [36] . The CD spectrum of α-I-
gliadin demonstrated a weak PPII signature with a positive peak close to 223nm. The 
shift in the positive peak towards lower wavelengths (from 229nm to 223nm) could be 
due to loss of tertiary amide chromophores and the presence of non prolyl residues in the 
sequence [36]. 
 
We estimated the PPII propensity of all the peptides present in the library as described 
previously by Creamer et al.[30]. Analogues A1 to A7, with Hyp substitutions at P3, P5 
and P8 positions demonstrated increased PPII helicities compared to the native α-I-
gliadin peptide (Figure 19). Analogue A2, containing 2 Hyp residues in its sequence at 
positions P5 and P8 displayed maximum PPII propensity among all analogues in the 
library, represented by highest ellipticity in the CD spectrum near 223nm. Analogues A3 
and A4 with Hyp residues at P3, P5 and P5, P8 respectively displayed greater PPII 
propensity compared to native α-I-gliadin peptide. Analogues A5, A6 and A7 which have 
a single Hyp amino acid substitution in position P8, P5 and P3 respectively displayed 
greater PPII propensity in comparison with native α-I-gliadin peptide, however they had 
lower PPII propensity in comparison with analogues A1, A2, A3 and A4 which had either 
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two or three Hyp amino acids in their sequence. The circular dichroism spectra of native 




Figure 19. Circular dichroism (CD) spectra of analogue library at pH 5.5 
Peptides dissolved in 1:1 mixture of PBS buffer and McIlvaine’s citrate-phosphate buffer to a 
final concentration of 35µM, final pH adjusted to5.5 and at temperature 370C. Each trace 
represents an average of ten scans. The presence of maxima near 223-225nm in spectra of 
peptides containing Hyp amino acid substitutions (analogues A1 to A7) represents PPII helical 
structure of these peptides. PPII signature cannot be observed in spectra of peptides containing N-




The CD spectra of N-Me-ala substituted analogues did not resemble a typical PPII helix 
spectrum, as evidenced by reduced or lack of positive peak near 223nm. Analogue A12 
with two N-Me-ala amino acids in its sequence at positions P5 and P8 had a maximum 
negative peak close to 227nm. The CD spectra of analogues A10 and A11 which have 
two N-Me-Ala amino acids in the sequence, along with analogues A8 and A9 with a 
single N-Me-ala substitution displayed lower PPII helical content compared to α-I-gliadin 
peptide. 
 
2.3.3 Evaluation of Association Rates of Structurally Diverse Analogues with 
Soluble HLA-DQ2 
 
After studying the secondary structure of α-1-gliadin analogues using CD spectroscopy, 
their association rates with HLA-DQ2 were measured by peptide exchange assay using 
an in vitro gel filtration method. Briefly, the fluoresceinated analogues were incubated 
with HLA-DQ2 and the complex formation (between analogues and DQ2) was analyzed 
quantitatively at various time intervals using gel filtration method. Upon injection of the 
sample into gel filtration column, the ‘DQ2- analogue complex’ eluted 2.5 minutes earlier 
than the unbound analogues, which were monitored as two seperate peaks on the 
chromatogram. Quantitative estimates of complex formation were evaluated by 




Overall, inducing structural changes in the analogues had a significant effect on their 
association rates with HLA-DQ2. In certain cases, like analogue A10, the increase in 
association rate was approximately 4.5 fold greater, compared to the native α-1-gliadin. 
Most of the analogues displayed increased association rates compared to native α-I-
gliadin peptide. 
 
Analogues with Hyp in position P3 (A1, A2, A3 and A7) did not associate with HLA-
DQ2. Analogues with Hyp substitutions in positions P5 or P8 displayed association rates 
similar to native α-I-gliadin, except for A6, which approximately had 2 fold higher 
binding rate compared to the native peptide. However, introducing Hyp residues in both 
positions P5 and P8 resulted in decreased association rates as evidenced in analogue A4 
which had Hyp amino acid in positions P5 and P8.  
 
Analogue A10 displayed the highest association rate compared to all other analogues in 
the library, which was approximately 4.5 fold higher than α-I-gliadin. A12 displayed 
moderately increased association rates while A11 displayed the least binding rate, among 
the methylated alanine peptides. Analogue A8 displayed the second highest association 
rate in the entire library. It had a 3.7 fold enhanced binding rate compared to native 
peptide. Analogue A9 exhibited a moderately increased binding rate compared to α-I-
gliadin. The displacement kinetics of α-I-gliadin and its analogues with HLA-DQ2 is 




Figure 20. Exchange reactions of α-I-gliadin peptide and its analogues binding to 
DQ2.  
0.2 µM fluorescent peptides were incubated with 5 µM DQ2at 37°C and pH 5.5 in a 1:1 mixture 
of PBS buffer and McIlvaine’s citrate-phosphate buffer. Fluorescent signals corresponding to the 
DQ2- peptide complex were compared to fluorescent peptide standard to obtain the concentration 
of the fluorescent peptide DQ2 complex and these values are represented as bound peptide 
percentage. Analogue A10 reached a maximum occupancy of 36% approximately, whereas the 
native gliadin peptide reached 8%. 
 
The impetus for investigating the contribution of secondary structure of ligands in 
associating with MHC molecules was to explore the possibility of developing MHC II 
blockers through structural modification of their ligands. In this case, some of the 
structurally modified analogues of α-I-gliadin displayed higher association rates to HLA-
DQ2 compared to the native peptide. Such analogues with superior association rates hold 
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the potential to outcompete the native gliadin peptide in binding to DQ2, thereby 
blocking its presentation to T-cells.    
 
In order to evaluate the efficacy of these structurally modified analogues as blockers, we 
quantified their blocking properties in antigen presenting cells expressing HLA-DQ2.  In 
this assay, we evaluated the efficiency of α-I-gliadin and its analogues to compete with γ-
gliadin (antigenic peptide from gluten protein) in forming a complex with DQ2.  
 
2.3.4 Proliferation Response of T-Cell Clones to Antigenic Peptide in the Presence of 
α-I-gliadin and Analogues  
 
Analogues A10 and A8 from the library were selected for this assay since they exhibited 
higher association rates in comparison with other members in the analogue library, as 
measured by the in vitro gel filtration experiment. P1298 (γ-II-gliadin, GIIQPEQPAQL) 
was used as the antigenic peptide. Two polyclonal T-cell lines, TCC 437.1.3.17 and TCC 
430.1.41 which have specific reactivity against γ-II-gliadin epitope were used in this 
assay. 
 
The antigenic peptide (γ-II-gliadin) was incubated with antigen presenting cells in the 
presence of α-I-gliadin and its analogues. These antigen presenting cells were later 
exposed to the T-cell lines. In this assay, α-I-gliadin and its analogues compete with 
antigenic peptide (γ-II-gliadin) to associate with HLA-DQ2 molecules present on antigen 
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presenting cells, therefore, the proliferation of T-cell lines is expected to be suppressed in 
the presence of α-I-gliadin and its analogues. As the analogues display superior binding 
ability to HLA-DQ2 in the in vitro binding assay, they are expected to suppress the 
proliferation of T-cell lines to a greater extent compared to α-I-gliadin peptide. At 100µM 
concentration, analogue A10 displayed 3.4 fold higher suppression of T- cell clone, TCC 
437.1.3.17 proliferation, compared to the native α-I-gliadin peptide. In the case of TCC 
430.1.41, A10 displayed a 1.9 fold greater inhibition of T- cell proliferation compared to 
the native peptide. A8 displayed 2.7 and 1.6 fold higher suppression of TCC 437.1.3.17 
and TCC 430.1.41 cell lines respectively compared to native α-I-gliadin. 
 
The reference peptide P198 (KPLLIIAEDVEGEY from Mycobacterium bovis 65 kDa 
Hsp 243–255Y), is known to be a very high affinity DQ2 ligand[37]. Interestingly, 
analogue A10 displayed 2.5 fold superior blocking ability of TCC 437.1.3.17 & TCC 
430.1.41 proliferation, compared to the tight binding P198 ligand. A8 displayed a 2.4 and 
2.1 fold enhanced suppression of the cell lines 437.1.3.17 & TCC 430.1.41 respectively, 
compared to this reference peptide. The cell proliferation response of T cell line, T.C.C. 
437.1.3.17 and T.C.C. 430.1.41, to antigenic peptide in the presence of α-I-gliadin and its 





Figure 21. Proliferative T cell responses of γ-II-gliadin responsive T cell line, T.C.C. 
437.1.3.17  
Proliferation of T.C.C. 437.1.3.17 in the presence or absence of selected blocker peptides, using 
fixed HLA-DR3/DQ2 homozygous B-lymphoblastoid cell lines (CD 114) as antigen presenting 
cells. P1298 - proliferation response to 2.5 µM antigenic γ-II-gliadin epitope (GIIQPEQPAQL), 
p198 - proliferation response to 2.5 µM antigenic γ-II-gliadin epitope, in the presence of various 
concentrations of DQ2 tight binding peptide p198 (KPLLIIAEDVGEY; Mycobacterium bovis 
65kDa heat shock protein 243-255Y). α-I-gliadin, A8, A10 are proliferation responses due to 
antigenic γ-II-gliadin epitope in the presence of varying concentrations of α-I-gliadin and its 
analogues A8 and A10 respectively. The suppression of T-cell proliferation is 3.4 fold higher in 






Figure 22. Proliferative T cell responses of γ-II-gliadin responsive T cell line, T.C.C. 
430.1.41  
Proliferation of T.C.C. 430.1.41 in the presence or absence of selected blocker peptides, using 
fixed HLA-DR3/DQ2 homozygous B-lymphoblastoid cell lines (CD 114) as antigen presenting 
cells. P1298 - proliferation response to 0.2 µM antigenic γ-II-gliadin epitope (GIIQPEQPAQL), 
p198 - proliferation response to 0.2 µM antigenic γ-II-gliadin epitope, in the presence of various 
concentrations of DQ2 tight binding peptide p198 (KPLLIIAEDVGEY; Mycobacterium bovis 
65kDa heat shock protein 243-255Y). α-I-gliadin, A8, A10 are proliferation responses due to 
0.2 µM antigenic γ-II-gliadin epitope in the presence of varying concentrations of α-I-g peptide 
and its analogues A8 and A10 respectively. The suppression of T-cell responses is 1.9 fold higher 





To ensure that the observed blocking effects of analogues A10 and A8, stem from their 
DQ2 binding abilities, the response of a HLA - DR3-restricted T cell clone (TCC RN.33) 
was measured in the presence of various concentrations of analogues, native peptide (α-1-
gliadin) and the reference peptide P198.  DR3/DQ2 homozygous B cell line was used for 
antigen presentation. The T-cell clone RN.33 (DR3-restricted) was stimulated with 10µM 
P261 (KTIAYDEEARR, DR3-restricted peptide; Mycobacterium tuberculosis 65kDa 
heat shock protein 3-13). None of the analogues were successful in suppressing the 
presentation of antigen to this specific T-cell clone, emphasizing the fact that these 
analogues are specific for DQ2-mediated antigen presentation. The cell proliferation 
response of T cell line TCC RN.33, to antigenic peptide in the presence of α-I-gliadin and 





















Figure 23. Proliferative T cell responses of T cell line, TCC RN.33 
Proliferation of TCC RN.33 in the presence or absence of selected blocker peptides, using fixed 
HLA-DR3/DQ2 homozygous B-lymphoblastoid cell lines (CD 114) as antigen presenting cells. 
P261 - proliferation response to 0.2 µM Mycobacterium tuberculosis 65kDa heat shock 
protein 3-13 antigenic peptide KTIAYDEEARR(DR3-restricted),  p198 - proliferation 
response to 0.2 µM antigenic peptide, in the presence of 0.4µM DQ2 tight binding peptide p198 
(KPLLIIAEDVGEY; Mycobacterium bovis 65kDa heat shock protein 243-255Y). α-I-g, A8 
and A10 are proliferation responses to 0.2 µM antigenic peptide in the presence of varying 
concentrations of α-I-g peptide and its analogues A8 and A10 respectively. The antigenic peptide 
elicited similar response against DR3 specific antigen in the presence of α-I-gliadin and its 





Autoimmune disorders (AD’s) encompass a diverse collection of diseases. There are over 
80 different autoimmune diseases, affecting millions of people across all age groups. 
AD’s display a strong correlation with expression of certain MHC molecules. For 
example, Rheumatoid Arthritis  is associated with class II MHC molecule HLA-DR4, 
Multiple Sclerosis has strong association with the expression of HLA-DR2 and HLA-
DQ6, and Type-1-Diabetes displays strong correlation with HLA-DQ8 and HLA-DQ6 
[38].  A common feature underlying AD’s is the presentation of an antigenic self peptide 
by a specific class II MHC molecule to CD4+ T-cells, which results in the activation of 
immune system and subsequent immune attack on self tissues. In this current work, the 
effect of modifying the secondary structure of antigenic peptides in forming a complex 
with class II MHC molecules was investigated and the potential of structurally modified 
antigenic peptide analogues to suppress the activation of specific T-cell lines was 
demonstrated. Such molecules can serve as starting point for developing potential drug 
candidates for patients with autoimmune disorders. 
 
 Previously, secondary structures were engineered into artificially designed host peptide 
sequences which had multiple repeats of a single or few amino acids. Kelly et al. [30] and 
Rucker et al. [31] used ‘Ac (Pro)3-X-(Pro)3GY-NH2’ as the host sequence, where position 
X was occupied by the incoming amino acid. Shi et al. [39] used AcGGXGG-NH2 as a 
host sequence to evaluate the secondary structure propensities of various amino acids. In 
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the current work, specific secondary structures (polyproline II) were successfully 
engineered into naturally occurring and more complex antigenic α-I-gliadin peptide.  
 
Previously, Cherng et al. [32] demonstrated that a stretch of poly L- Hydroxyproline 
adopts a PPII helix conformation in solution, and has greater propensity to form PPII 
helical structure than poly-L-Proline. Although, host-guest studies were not performed 
with Hyp to evaluate the contribution of a single Hyp residue in promoting PPII helix 
conformation, the present work demonstrates that substituting Pro with Hyp increases the 
PPII propensity of peptides as evident in the CD spectra of analogues A1 to A7 (figure 
19).  
 
From the in vitro gel filtration experiments, analogues containing ‘Hyp’ amino acid in P3 
(A1, A2, A3 and A7) did not show any association with HLA-DQ2. Detailed observation 
of the crystal structure of α-I-gliadin peptide in complex with HLA-DQ2 revealed that the 
imino ring of Pro in P3 position points towards the binding pocket of HLA-DQ2. 
Therefore, substituting Pro in P3 position with a more bulky Hyp could potentially cause 
stearic hindrance and this could prevent analogues having Hyp in P3 position from 
forming a complex with HLA-DQ2. Analogue A4 with 2 Hyp substitutions at P5 and P8 
positions displayed a lower association rate with HLA-DQ2 in comparison with native α-
I-gliadin peptide (figure 20). A possible explanation for this phenomenon is that, 
substitution of Pro with Hyp residues in the sequence, increases the PPII propensity of 
Hyp containing analogues, and therefore leads to a more rigid backbone conformation of 
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the peptide. This increased rigidity of the peptide backbone could be unfavorable to 
sample the conformatory space before adopting the optimal conformation required for 
associating with HLA-DQ2, and therefore could lead to decreased association rate. In the 
case of analogues A8 and A10, Pro in positions P3, P5 and P8 was replaced with N-Me-
ala amino acid. These analogues did not display typical PPII signature in their CD 
spectra, however, they demonstrated superior association with DQ2 in comparison with 
the native α-I-gliadin peptide (figure 20). The substitution of Pro with N-Me-ala could 
result in greater flexibility of the peptide backbone, as the imino ring of Pro no longer 
restricts the conformatory freedom of the peptide backbone, and this in turn enables the 
peptide to sample the conformatory space with greater ease, before adopting the final 
bound conformation. This change in the backbone conformation could be responsible for 
the higher association rate displayed by N-methylated alanine substituted analogues. 
 
Analogues A8 and A10 displayed greater suppression of T cell proliferation compared to 
α-I-gliadin peptide in the T-cell proliferation assay (figures 21 and 22). Since these 
analogues display superior association rate with HLA-DQ2 in the in vitro gel filtration 
assay (figure 20), it could be hypothesized that they would associate with greater number 
of DQ2 molecules on the surface of antigen presenting cells compared to native α-I-
gliadin peptide, and this in turn could lead to superior suppression of T-cell proliferation. 
 
Previously, DQ2 blockers were designed by Xia et al. [29], using the 20 mer α-II-gliadin 
sequence as a template. They synthesized dimerized analogues which display a high 
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affinity of binding to DQ2. These analogues were superior T-cell blockers compared to 
the unmodified peptide. However, this method requires extensive chemical modifications 
that are tedious to accomplish. This work highlights the design of structurally modified 
monomeric analogues of antigenic peptide which display enhanced binding to DQ2 and 
superior T-cell blocking ability compared to the native gliadin peptide.  
 
In summary, structurally diverse analogues of the antigenic peptide, α-I-gliadin was 
successfully designed. These analogues, by virtue of their enhanced association rates to 
HLA-DQ2, were successful in inhibiting the DQ2 facilitated presentation of antigenic 
peptides to two different sub classes of disease specific T-cells. One of the merits of this 
strategy lies in the fact that it can be readily adapted to several other antigenic peptides 
that associate with class II MHC molecules like HLA-DQ8, HLA-DQ6, that are strongly 
associated with diseases like Type-1-Diabetes and Narcolepsy respectively. Since all 
antigenic peptides bound to MHC II molecules have certain residues exposed to the 
solvent, it should be feasible to generate structural analogues of these antigenic peptides 
through modification of the solvent exposed residues. Such structurally modified 









3.1.1 Plasma Membrane 
 
All prokaryotic and eukaryotic cells are shielded by a double layered membrane, namely 
plasma membrane. The plasma membrane is a phospholipid bilayer, which separates the 
internal components of the cell from the extracellular environment. This membrane is 
selectively permeable, regulating the trafficking of substances, wherein it allows the 
transport of small non-polar substances unhindered compared to the movement of 
charged entities like ions.  
 
Phospholipids are an important constituent of plasma membrane. They are molecules 
composed of hydrophilic phosphate head group (phosphatidyl choline, phosphatidyl 
serine etc), and a hydrophobic lipid tail. Phospholipids provide the structural framework 
to the membrane. They are composed of fatty acids and phosphatidyl groups joined 
together through glycerol or sphingosine moiety. In the plasma bilayer membrane, the 
phospholipids are arranged in a tail to tail fashion exposing the charged phosphatidyl 
groups to the extra and intracellular environment.   
 
Proteins constitute an important part of these membranes, and they can be attached to the 
surface or embedded in the membrane, spanning its entire breadth. Proteins associated 
with membranes carry out several important functions like signaling, ion transport and 
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cell-cell communication. Cholesterol, an important constituent of the membrane is 
required to establish proper membrane permeability and fluidity [40].  
 
The lipids in the cell membrane perform several important functions. They participate in 
energy storage, act as messengers, and to facilitate the budding of the membrane. This 
feature plays a pivotal role in transport of several components across the plasma 
membrane 
 
3.1.2 Membrane Transport 
 
Small hydrophobic molecules and gases such as oxygen and carbon dioxide freely diffuse 
across the plasma membrane, but molecules having an overall charge and high molecular 
weight are relatively impermeable. Transport of charged molecules is usually facilitated 
by membrane bound ion transporters. Large substances are transported by a process 
called endocytosis. In this process, the plasma membrane invaginates and pinches off into 
the cell after engulfing large particles. This endocytic process can be further divided into 
2 main pathways namely phagocytosis and pinocytosis. Despite the variability in the 
endocytic pathways, they all share some basic steps, which start with invagination of the 
membrane into a vesicle termed endosome. This endosome pinches off from the 




Phagocytosis involves ingestion of large particles such as bacteria and cell debris, and is 
restricted to specialized cells such as macrophages, monocytes, and neutrophils. Other 
types of endocytic mechanisms include clathrin mediated endocytosis (CME), caveolin 
mediated endocytosis (CaME), clathrin & caveolin independent endocytosis, and 
macropinocytosis. 
3.1.2.1 Clathrin Mediated Endocytosis (CME) 
 
CME is one of the best characterized endocytic pathways and occurs in all mammalian 
cells. This process plays an important role in the recycling of plasma membrane and 
synaptic vesicle membrane proteins after neurotransmission. It also facilitates the uptake 
of important nutrients such as transferrin and growth factor receptors. Adaptor proteins 
like AP2 and ARH play an important role in initiation and assembly of clathrin coated 
vesicles (CCV). After the nucleation of CCV, ENTH domain containing proteins like 
epsin and enthoprotin play an important role in driving the curvature of these vesicles. 
Proteins like dynamin drive the scission of these CCV which is followed by their 
uncoating facilitated by proteins such as HSP70.  After completion of uncoating, these 
vesicles are transported along the endocytic pathway by cytoskeleton proteins such as 
actin, resulting in the entry of extracellular components into the cell. There are two main 
intracellular trafficking routes, the recycling route and the lysosomal route. The 
regulation of trafficking is determined by signal sequences found on the receptor and by 
scaffolding proteins. The recycling route targets the vesicles back to membrane whereas 
57 
 
the lysosomal route targets the vesicles and its cargo to lysosomes which contain various 
degradative proteases that degrade engulfed cargo molecules [41, 42].  
3.1.2.2 Caveolae Mediated Endocytosis 
 
Unlike clathrin mediated endocytosis, caveolae mediated endocytosis is a non classical 
endocytic pathway. Internalization of sphingolipid binding toxins, such as the cholera 
toxin, growth-hormone receptors, and viruses such as Simian virus 40 are carried out by 
this pathway. Caveolae, are flask shaped invaginations of plasma membrane. Dimeric 
membrane proteins like caveolin 1, 2 and 3 insert in the membrane and self assemble to 
create a coat on the surface of the membrane invagination. Apart from caveolin proteins, 
kinase mediated disruption of the actin cytoskeleton and recruitment of dynamin is 
crucial for the budding of caveolae from the plasma membrane. Unlike CME, caveolae 
mediated endocytosis is present in specific cells like adipocytes and myocytes.   
3.1.2.3 Clathrin and Caveolae Independent Endocytosis 
 
There are several other pathways which operate independent of clathrin and caveolin 
mediated endocytosis. An example is the GPI-AP enriched early endosomal pathway 
which takes up fluid phase markers like proteoglycans.  Another example includes 
flotillin mediated endocytosis, wherein flotillins, which are hairpin-structured integral 






This is a well established form of pinocytosis mediated by ruffling of the plasma 
membrane, resulting in the formation of vacuoles, called macropinosomes. Bulk uptake 
of fluid is mediated through this process. Phosphatidylinositol-2-phosphate (PIP2) and 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) play an important role in this process. 
Other proteins like BAR domain proteins and proteins belonging to SNX (sortin nexin) 
family have been implicated in membrane curvature. Several kinases like Arf6, Ras 
GTPase, and Src kinase play a crucial role in this process. The trafficking of 
macropinosomes is mainly accomplished by actin network, which results in the fusion of 
macropinosomes with other endosomes as observed in macrophages or in their recycling 
back to the membrane [43]. 
 
3.2 Cell Penetrating Peptides 
 
CPP are short peptides, usually in the range of 8 to 50 amino acids in length and have the 
ability to cross plasma membrane and gain entry into cells. When cargo molecules are 
attached to CPPs, they also transport the cargo molecules across the cell membrane, into 
the cell. This cargo ferrying ability of CPPs has found useful applications in delivery of 
therapeutic and diagnostic molecules into cells and other applications in research and 
development. These CPPs can adopt one or more of the endocytic pathways to gain entry 
into cells. Certain CPPs are also known to enter cells through passive diffusion. 
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3.2.1 History of Cell Penetrating Peptides 
 
In 1988, while developing an assay to measure the activity of tat protein from the human 
immunodeficiency virus 1 (HIV-1), Frankel et al. [44] discovered that the purified TAT 
(transactivator of transcription) protein could be taken up by cells growing in tissue 
culture and subsequently trans-activate the viral promoter. Further research on TAT 
protein resulted in the discovery of the first CPP, TAT, a ten amino acid long peptide 
with the sequence GRKKRRQRRR. In 1991, Antennapedia homeodomain protein - a 
transcription factor from Drosophila, was also shown to possess similar translocation 
ability [45]. This led to a rapid design and development of peptide sequences with cell 
penetrating properties and the ability to carry various cargo molecules into cells. Several 
other CPPs like transportan, model amphipathic peptide (MAP), Pep-1, polyarginine, and 
pVEC were developed in the past few years [46]. Table 2 provides examples for some of 














Table 2.  Amino acid sequences of well characterized cell penetrating peptides 
 
A common feature underlying most of the current CPPs is the presence of positively 
charged amino acids like Arginine (R) and Lysine (K).  Recently, Sweet Arrow Peptide 
(SAP) a proline-rich CPP which also has an overall positive charge has been discovered.  
 
3.2.2 Mechanism of Entry  
 
The proposed internalization mechanism for CPPs has changed in the past 20 years. 
Initially, CPPs were thought to gain entry through direct translocation, since 
internalization occurred in an energy independent manner. Peptides synthesized using D-
amino acids mimicking the sequence of natural CPPs displayed cell penetration 
Peptide Sequence Reference 
Penetratin RQIKIWFQNRRMKWKK [47] 
Tat(48-57) GRKKRRQRRR [48] 
Poly Arginine (R8) RRRRRRRRR [49] 







SAP (Sweet Arrow Peptide) (VRLPPP)3 [53] 
Bactenecin RLCRIVVIRVCR [54] 
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properties similar to the original CPP composed of L-amino acids. This indicated that 
chiral receptors were not involved in the uptake process[55]. 
 
Recently, various endocytic mechanisms like CME and caveolin mediated endocytosis 
are being proposed as the route of entry for these CPPs, however, no consensus in 
internalization mechanism of CPPs has been reached[56]. Direct translocation methods 
were implied in case of certain CPPs (e.g. TAT) although such mechanisms have not 
been conclusively demonstrated for other CPPs[56, 57]. Currently, CPPs are thought to 
adopt more than one route of entry to gain access to the intracellular compartments [58]. 











Figure 24. Schematic representation of possible entry mechanisms of CPPs into cells 
 
CPPs adopt multiple approaches to gain entry into cells. Adoption of a specific mechanism of 
entry depends on the charge, hydrophobicity of peptide and the nature of cargo attached to CPPs. 
The various entry mechanisms include phagocytotic and pinocytotic pathways: clathrin-mediated 
endocytosis, caveolae-mediated endocytosis, and macropinocytosis 
3.2.3 Cargo Delivery 
 
 
Various cargo molecules have been successfully delivered using CPPs. Some of the 
important types of cargoes include organic molecules, proteins, nucleic acids etc. Most of 
these cargoes were delivered into a variety of mammalian cell lines, cultured in vitro.  In 
several instances, cargo attached to CPP was reported to influence the efficacy of 




penetration of the peptide and also the route of entry. A few examples of cargoes that 
have been successfully delivered using CPPs are mentioned in Table 3. 
 
Table 3. Examples of various cargo molecules delivered by cell penetrating peptides 
Type of Cargo Cargo Peptide Cell Type 
Peptide PKC Inhibitor 
(Peptide) 
Penetratin Neuronal and 
astrocyte 
PCw3 Penetratin Macrophage 
Rab 1 and 2 Penetratin Prolactin cells 
Cdk-4 and Cdk-6 
inhibitors 
Penetratin HaCaT cells 
P16 inhibitor Penetratin Pancreatic cells 
VHL Tat In vivo 
Protein RNase A Tat In vivo 
Bcl-xL Tat Neuron  
Caspases 2 and 8 Tat Isolated rat heart 
Smac Tat & Penetratin MCF 7 cells 
Oligonucleotide SOD1 Penetratin Neuron 
βAPP Penetratin Neuron 
MDR-1 Tat 3T3 fibroblasts 
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Large Particles pCMV - Luc Tat-branched Cos-1 & 3T3 cells 
Magnetic 
nanoparticles 
Tat Progenitor cells and 
In vivo 
 
3.2.4 Limitations of existing CPPs 
Although CPPs were discovered two decades ago, their applications were restricted 
mainly to in vitro research purposes. One major drawback of existing CPPs is their 
susceptibility to proteases. None of the existing CPPs, which are composed of natural 
amino acids, have shown resistance to proteases. This is one of the main obstacles 
preventing the use of CPPs for in vivo applications. Development of novel CPPs resistant 
to human digestive and serum proteases might facilitate the application of CPPs for in 
vivo applications. 
 
3.2.5 Discovery of 33mer - A novel CPP from gliadin proteins 
3.2.5.1 Gliadin proteins 
Gliadins are a class of proteins found in wheat. They comprise a family of proline and 
glutamine rich proteins and constitute major component of wheat protein[59]. Based on 
solubility, gliadins are classified into α/ β gliadins, γ gliadins and ω-gliadins. Previous 
work on 33 amino acid (33mer) long peptide from α-II-gliadin, in the context of celiac 
disease research provided information about its structure which led to the investigation of 
its potential as a CPP.  
 
Source:  Drug Discovery Today, 2004, 9(23), 1012-1019 
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The amino acid sequence of 33mer peptide is NH2- 
LQLQPFPQPELPYPQPELPYPQPELPYPQPQPF-COOH. The 33mer peptide was 
manually synthesized using chemical methods and its potential to transport fluorescent 
molecules was explored using flow cytometry and confocal microscopy.  The protease 
susceptibility of 33mer in comparison with other existing well established CPPs was 
carried out and the superior protease resistance of the 33mer peptide was successfully 
demonstrated. After evaluating the cell penetration properties of 33mer peptide, the probability 
of developing shorter CPP derived from 33mer peptide was explored.  
 
3.3 Experimental Procedures 
3.3.1 Peptide Synthesis, Labeling, and Purification 
 
The peptides used in this study were prepared using Fmoc/HBTU chemistry based solid 
phase peptide synthesis (SPPS) with Wang resin as the solid support. The N-terminal of 
peptides used in this study were labeled separately with 5,6 carboxy fluorescein (FAM) 
and 5,6 carboxy tetramethylrhodamine (TAMRA) and CyNA 414 (near infra-red dye) 
using N,N'-diisopropylcarbodiimide (DIC) and 1-Hydroxybenzotriazole (HOBt) in 1:1 
Dimethyl formamide (DMF) and dichloromethane (DCM) as solvent. After completion 
of synthesis, peptides were cleaved from resin in Trifluoroacetic 
acid/Triisopropylsilane/Water (TFA/TIS/H2O 95:2.5:2.5, v/v/v) for 4 hours and 
precipitated in ice cold Methyl Tert-Butyl Ether (MTBE). Crude peptides were 
lyophilized and were purified by reverse-phase HPLC on a semi-preparative C18 column 
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using a water-acetonitrile gradient in 0.05% (v/v) TFA, to purity greater than 95%. The 
purity and identity of the peptides were confirmed by liquid chromatography coupled 
electron spray mass spectrometry (LC-MS). The pure fractions were lyophilized and 
stored at −20°C. 
 
3.3.2 Mammalian Cell Culture 
 
HeLa cells (ATCC) were grown in medium containing DMEM, fetal bovine serum (FBS) 
(10%), penicillin (100U/ml) and streptomycin (100µg/ml). The cells were maintained in 
humidified incubator at 37ºC, 5% CO2. Cells were grown to 90-100 % confluence 
monolayer in 100-mm diameter tissue culture dishes. 
 
3.3.3 Flow Cytometry Analysis 
 
Approximately, 1 x 105 cells, freshly collected at 80-90% confluency were incubated 
with 50µM of FAM (5,6 carboxy fluorescein) labeled 33mer and equal volume of growth 
medium (DMEM, 10%FBS and penicillin/ streptomycin) at 37ºC, and 5% CO2 for one 
hour. After incubation, cells were trypsinized and washed thrice with DPBS buffer (PBS 
deficient in Ca2+ and Mg2+) supplemented with 0.5mM EDTA, by spinning and 
resuspending the cells alternately.  After thorough washing, the cells were resuspended in 
500ul DPBS buffer. Just before the flow cytometry analysis, 500ul of 2mg/ml trypan blue 
was added to the sample [60]. Flow cytometry analysis was performed on DAKO 
Cytomation Cyan LX system and a minimum of 10,000 events were collected for each 
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sample. Cell debris was excluded from analysis. Cells with compromised membrane 
stained by trypan blue were not taken into consideration when deducing fluorescence 
intensity. Autofluorescence of cells was also subtracted from fluorescence intensity of 
each individual sample using histogram subtraction. Fluorescence intensity measurement 
was carried out as triplicates.  
 
3.3.4 Confocal laser scanning microscopy 
 
15,000 HeLa cells were seeded onto each well of eight-well chambered coverslips 
(Molecular Probes) and grown overnight. The following day, cells were incubated with 
5µl of 100µM 33mer peptide coupled to TAMRA (TAMRA-33mer) and diluted with 
equal volume of DMEM medium, and in the case of 12mer and TAT, 20µl of 50µM 
FAM labeled peptides were diluted with equal volume of DMEM medium and incubated 
for one hour at 37ºC, and 5% CO2. After incubation with peptide, cells were thoroughly 
washed (3 washes) with PBS before imaging. Cells were imaged using a laser scanning 
microscope, Carl Zeiss LSM510 Meta, mounted on an Axiovert 200M inverted 
microscope. TAMRA was excited at 543nm using a He-Ne gas laser and FAM labeled 
peptides were excited at 488nm using Ar laser.  
 




Protease susceptibility of the 33mer was compared with 3 commercially available CPPs, 
namely TAT, Penetratin and Transportan in an in vitro protease resistance assay [61]. 
The peptides were incubated with gastric and pancreatic digestive enzymes at a molar 
ratio of 100: 1 (peptide: enzyme).  30 nanomoles of the peptides were initially incubated 
with pepsin at pH 2.0 for 30 min. The pH of this mixture was adjusted to 7.0 and was 
further incubated with 4 other digestive enzymes, namely Trypsin, Chymotrypsin, Elastin 
and Carboxypeptidase for 2 hrs at 370 C. After incubation, the enzymes were inactivated 
by maintaining the reaction mixture at 950C for 10 min. In order to separate the high 
molecular weight impurities, formed by the digestion of enzymes in the reaction mixture, 
the reaction mixture was filtered using a 10,000 MWCO membrane filter. Filtrate was 
concentrated and was subjected to LC analysis.  
 
3.3.6 In vivo and ex vivo imaging of CyNA 414-33mer conjugate 
 
Mice obtained from the Biological Resource Centre (A*STAR Bio-medical Sciences 
Institutes) were anesthetized by intraperitoneal injection of ketamine (150 
mgkg1)/xylazine (10 mgkg1) at the age of 8 weeks. CyNA 414 - 33mer conjugate and 
CyNA 414 dye alone (0.1µ mol in PBS, 0.5ml) were administered through oral route 
(P.O. - per os) by using a bulb tipped gastric gavage needle attached to a syringe .The animals 
were placed in an IVIS spectrum imaging system (Caliper life Sciences) immediately and 
the fluorescence image was acquired using the 745 nm excitation and 820 nm emission 
filters. Forty eight hours later, organs were harvested and images were acquired using the 
IVIS system and imaged with the same setting used for in vivo studies. All animal 
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experiment procedures were performed in accordance with a protocol approved by the 
Institutional Animal Care and Use Committee. 
 
3.4 Results 
3.4.1 HPLC and Mass Spectrometry Analysis of 33mer 
 
The 33mer peptide was purified on Shimadzu LC-6AD preparative HPLC using 
Phenomenex C18 semi preparative column. Two buffers, Buffer A (98% H20, 2 % 
Acetonitrile and 0.05% Trifluoroacetic acid) and Buffer B (80% Acetonitrile, 20% H2O 
and 0.04% Trifluoroacetic acid) were used for purifying the peptide. Final purity of the 
peptide was confirmed by using a C18 analytical column. The LC chromatogram and 




















Figure 25. Liquid chromatogram profile of peptide 33-mer. Chromatographic conditions: 
Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 98%water + 2% ACN + 0.05% 






Figure 26. ESI-MS of peptide 33-mer. ESI-MS of 33- mer dissolved in 0.1% TFA aqueous 
solution. Expected Molecular Weight: 3911.9 Da [MH] +, 1305 Da [MH3]3+ 
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3.4.2 Quantitative Analysis of Cell Penetration of 33mer in HeLa Cells using Flow 
Cytometry 
 
The uptake of the FAM-33mer conjugate into HeLa cells was evaluated and compared 
with FAM-Tat peptide using flow cytometry. In order to ensure an accurate estimation of 
cell penetration, cells were washed thrice using DPBS buffer (PBS deficient in Ca2+ and 
Mg2+) to remove the fluorescent peptides on the cell surface. Before flow cytometry 
analysis, the cells were mixed with equal volume of DPBS buffer and 2 mg/ml of trypan 
blue in order to quench the fluorescence due to peptides attached to external cell surface 
if any [60]. The relative fluorescence values due to the entry of FAM labeled CPPs into 
cells, as measured by flow cytometry is represented in figure 27 
 





Figure 27. Cell penetration analysis of 33mer peptide. The flow-cytometric analysis was 
performed with Dako Cytomation Cyan LX flow cytometer using 488 nm laser for excitation of 
fluorescent dye (FAM) attached to peptides. Analytical gates were applied to account for the auto 
fluorescence originating from cells alone. From the flow cytometric analysis, 33mer peptide 
displayed 1.5 fold increased cell penetration compared to Tat. YDEGE peptide was used as 

































3.4.3 Microscopy Analysis of Cell Penetration of 33mer Peptide 
 
To gain a better understanding of the entry of 33mer into cells and its distribution, 
confocal microscopy experiments were performed on cells incubated briefly with 
TAMRA labeled 33mer peptide. Figure 28 shows confocal microscopy images of HeLa 



















Figure 28. Confocal Microscopy Analysis of HeLa Cells Incubated with TAMRA alone and 
TAMRA labeled 33mer. (a) fluorescent and (b) bright field image of HeLa cells incubated with 
TAMRA dye alone. (c) fluorescent and (d) bright field image of HeLa cells incubated with 
TAMRA labeled 33mer peptide. 15,000 HeLa cells grown overnight were incubated with 5µl, 
100µM of TAMRA alone or TAMRA labeled 33mer peptide and diluted with equal volume of 
DMEM medium, and incubated for one hour at 37ºC, and 5% CO2. After incubation, cells were 
washed thrice with PBS before imaging. Images were acquired using Carl Zeiss LSM510 Meta, 
mounted on an Axiovert 200M inverted microscope with 40× plan-neofluar NA0.75 DIC. 
TAMRA was excited at 543nm using a He-Ne gas laser.  
 
a  b  
c d  
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HeLa cells incubated with dye alone (TAMRA), they did not show any fluorescence 
inside the cells. The fluorescence signal was localized mainly on the outer boundary of 
cells. Confocal microscopy images of cells incubated with TAMRA labeled 33mer 
peptide, displayed a punctuate distribution of the peptide inside the cells. This suggests 
that 33mer peptide was successful in entering the cells and also ferrying the TAMRA dye 
along with it into the cells.  
 
3.4.4 Protease Degradation Analysis of Tat, Penetratin, Transportan and 33mer 
 
Protease susceptibility of the 33mer peptide and 3 other commercially available CPPs 
was tested using the in vitro protease resistance assay. Briefly, the peptides were 
incubated with digestive enzymes Pepsin, Trypsin, Chymotrypsin, Elastin and 
Carboxypeptidase at appropriate pH. After incubation, the integrity of the CPPs was 
analyzed using HPLC. Of all the peptides, only 33mer displayed resistance against all the 
digestive proteases used in the assay. The other commercially available CPPs were 
digested into small fragments by the proteases. This can be clearly observed by 
comparing the LC profiles of CPPs before and after incubation with digestive enzymes 
(Figures 29 - 32).  After incubation, a clear increase in the number of peaks at different 
retention times was observed, compared to the intact CPP (LC profile before incubation 
with proteases), representing the degradation of peptide into smaller fragments. This 
protease resistant property of 33mer demonstrates its potential for cargo delivery 








Figure 29.  LC profile of 33mer. Liquid chromatogram of the 33mer A) before incubation 
with digestive proteases, B) after incubation with digestive proteases. After incubation with 
proteases, the majority of the 33mer peptide still remains intact. Chromatographic conditions: 
Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 98%water + 2% ACN + 0.05% 
TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, Gradient: 0 - 80% B in 80 min. Retention 
















































Figure 30.  LC profile of Penetratin. Liquid chromatogram of Penetratin A) before 
incubation with digestive proteases, B) after incubation with digestive proteases. After incubation 
with proteases, Penetratin peptide gets digested into multiple fragments. Chromatographic 
conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile phase: Buffer A: 98%water + 2% ACN 
+ 0.05% TFA, Buffer B: 80% ACN + 20% water + 0.04% TFA, Gradient: 0 - 80% B in 80 min. 











































Figure 31.  LC profile of Transportan. Liquid chromatogram of Transportan A) before 
incubation with digestive proteases, B) after incubation with digestive proteases. After incubation 
with proteases Transportan peptide gets digested into multiple fragments which have shorter 
retention time compared to undigested peptide. Chromatographic conditions: Luna C-18 (150 mm 
× 3.0 mm, 3µm); mobile phase: Buffer A: 98%water + 2% ACN + 0.05% TFA, Buffer B: 80% 
ACN + 20% water + 0.04% TFA, Gradient: 0 - 80% B in 80 min. Retention time is displayed on 
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Figure 32.  LC profile of TAT. Liquid chromatogram of TAT A) before incubation with 
digestive proteases, B) after incubation with digestive proteases. After incubation with proteases 
TAT peptide gets digested into multiple fragments which have shorter retention time compared to 
undigested peptide. Chromatographic conditions: Luna C-18 (150 mm × 3.0 mm, 3µm); mobile 
phase: Buffer A: 100%water + 0.1% TFA, Buffer B: 10% ACN + 90% water + 0.1% TFA, 























































3.4.5 Evaluating Cell Penetration Ability of Truncated 33mer Through Confocal 
Microscopy Analysis 
 
To evaluate the cell penetration potential of truncated 33mer peptide, the cargo ferrying 
ability of 12 amino acid long peptide derived from 33mer, with sequence 
‘QLQPFPQPELPY’ was evaluated, as shorter CPPs are advantageous due to lower cost 
of synthesis. To test the in vivo suitability of the 12mer peptide and compare it with some 
of the existing CPPs, the 12mer and TAT peptides were incubated in digestive proteases 
(Pepsin, Trypsin, Chymotrypsin and Carboxypeptidase) and then the cell penetration 
ability of these peptides was evaluated after incubation with proteases using confocal 
microscopy analysis. As represented in figure 33, 12mer peptide demonstrated superior 





























Figure 33. Confocal analysis of cell penetration ability of 12mer and TAT peptides 
(a) Confocal image of  TAT before incubation with proteases (b) Confocal image of  TAT after 
incubation with proteases. Confocal images of 12mer peptide, (c) before and (d) after incubation 
with proteases. After incubation with proteases, 12mer peptide shows superior cell penetration in 
comparison with TAT. HDF cells seeded in Corning Incorporated Costar 96 well plates for 48 
hours were incubated with 50µM FAM labeled peptides, with equal volume of culture medium 
for 1 hour. After incubation, cells were washed 3 times with PBS before confocal microscopy. 
Images were acquired using Carl Zeiss LSM510 Meta, mounted on an Axiovert 200M inverted 
microscope with EC Plan-Neofluar 10x/0.30. FAM was excited at 488nm using a Ar gas laser 






3.4.6 In vivo Cargo Delivery Analysis of 33mer Administered through Oral Route 
 
To demonstrate in vivo cargo delivery by 33mer, CyNA414 labeled 33mer peptide (0.1µ 
mol in PBS, 0.5ml) was administered to 8 week old mice through P.O.. The animals were 
placed in an IVIS spectrum imaging system (Caliper life Sciences) immediately and the 
fluorescence image was acquired using the 745 nm excitation and 820 nm emission 
filters. To highlight the cargo delivery ability of 33mer, CyNA 414 dye alone was also 
used in these experiments, as a control.  As seen in figure 34, the dye and dye labeled 











Figure 34. Administration of CyNA414 and CyNA414 - 33mer conjugate through 
gastric gavage 
In vivo imaging of 8 week old mice administered with a) Phosphate Buffered Saline (PBS) b) 
CyNA414 and c) CyNA414 - 33mer conjugate through gastric gavage. Images were acquired 
immediately after administration of peptide using IVIS spectrum imaging system (Caliper life 
Sciences) using the 745 nm excitation and 820 nm emission filters. The fluorescent signal from 
the abdominal region represents localization of dye alone and dye labeled 33mer in the stomach 
 
 
Forty eight hours later, mice were sacrificed, organs harvested and imaged for 
fluorescence detection. As shown in figure 35, fluorescence signal was detected in the 
lung tissue of mice administered with CyNA414 coupled to 33mer peptide. A possible 
explanation for this observation is that dye coupled 33mer peptide localized in the lung 
tissue after successfully crossing the intestinal lining and entering the circulatory system. 
a b c 
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However, factors contributing to the preferential localization of the 33mer peptide in lung 
tissue need to be investigated.  No fluorescence signal was detected in mice administered 
with CyNA414 dye alone. 
 
 
Figure 35. Localization of CyNA-33mer conjugate, 48 hours after administration 
In vivo imaging of organs harvested from mice administered with a) Phosphate Buffered Saline 
(PBS) b) CyNA414 and c) CyNA414 - 33mer conjugate, 48 hours after administration of the 
peptide. Images were acquired with IVIS spectrum imaging system using the 745 nm excitation 
and 820 nm emission filters. CyNA-33mer conjugate localized in the lungs of mice while no 
fluorescent signal was detected in mice administered with CyNA414 dye alone. 

















Discovery of CPPs holds great promise for efficient delivery of macromolecules across 
membrane barriers. Initial experiments on HIV-1 transactivating (TAT) protein resulted 
in the discovery of the first CPP, namely TAT. The antennapedia domain of Drosophila 
was later discovered to harbor cell penetration properties too. Several CPPs were 
discovered in the past decade and currently, there are more than 40 different CPPs 
reported in the literature. An important feature of these CPPs is their ability to transport 
cargo attached to these peptides, into the cells. This feature enables the delivery of 
different types of molecules into cells. Different types of peptides, proteins, nucleic acids, 
organic molecules, quantum dots have been delivered into cells using various CPPs.  
 
Inspite of several efforts, the cellular entry mechanisms of CPPs are not completely 
elucidated. Several mechanisms have been attributed to explain their cell penetration 
mechanism. Endocytosis has been mainly implicated in the penetration of these peptides 
into cells. It was demonstrated that CPPs use several endocytic mechanisms like Clathrin 
and Caveolin mediated endocytosis, Macropinocytosis and even passive diffusion 
mechanisms. Cellular entry mechanism of the 33mer peptide is not conclusively known.  
From the punctuate distribution of 33mer peptide in the confocal images, we speculate 
that endocytosis may be the route of entry. However, a thorough investigation must be 
carried out to decipher the precise entry mechanism. Inhibitors of specific endocytic 
pathways like Chlorpromazine (inhibitor of clathrin mediated endicytosis), Nystatin 
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(inhibitor of caveolae mediated endocytosis), Wortmannin (inhibitor of 
macropinocytosis) can be used to probe the entry mechanisms of 33mer peptide.  
 
One of the major factors restricting the use of CPPs for in vivo applications is the 
susceptibility of existing CPPs to serum and digestive proteases. Most of the existing 
CPPs reported in the literature, which are composed of natural amino acids are 
susceptible to degradation by digestive proteases.  To address this limitation, CPPs 
composed of D-amino acids were synthesized and were shown to work efficiently[63]. 
However, this process is tedious and is not commercially viable. Recently, a new strategy 
for stabilizing α-helices through hydrocarbon stapling of peptides was reported.  Such 
stapled peptides demonstrated good cell penetration ability, apart from other features[64]. 
However, this methodology involves modification of natural peptides to accommodate 
the hydrocarbon staple used to stabilize the α-helical structure of the peptide. Compared 
to existing CPPs, 33mer peptide has several merits. This peptide is completely composed 
of natural amino acids, yet it exhibits resistance against multiple digestive proteases 
including Pepsin, Trypsin, Chymotrypsin, and Carboxypeptidase (figure 29). Other CPPs 
that are composed of natural amino acids, and not subjected to any modifications do not 
exhibit resistance against proteases (figures 30-32). Due to its protease resistant nature, 
33mer peptide successfully delivered CyNA414 dye into the lungs of mice when the dye-
peptide conjugate was administered orally. In contrast, no fluorescence signal was 
observed when the dye was administered alone (figure 35). This result suggests that 
33mer peptide was successful in ferrying the dye molecule across the intestinal barrier 
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into the blood stream, and delivered the cargo molecule specifically to lungs when the 
images were acquired 49 hours after peptide administration. As images were not acquired 
at shorter time intervals, the possibility of localization of dye-peptide conjugate in other 
organs cannot be ruled out. Further experiments must be carried out to understand the 
factors contributing to the preferential localization of the 33mer peptide in lung tissue. 
The superior cell penetration ability of the shorter 12mer peptide in comparison with 
TAT, after incubation with digestive proteases demonstrates the in vivo cargo delivery 
potential of this peptide (figure 33).  
 
In conclusion, 33mer and 12mer peptides exhibit a unique combination of protease 
resistance and cell penetration properties which highlight their potential as promising in 
vivo cargo delivery agents. Further research on the cell penetration mechanisms of these 
peptides and their ability to transport different types of cargoes into various cell lines 
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